{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:50:44Z","timestamp":1778799044548,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-03925-x","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:06:13Z","timestamp":1718622373000},"page":"620-630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of luseogliflozin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"86","author":[{"given":"Reddikumar Reddy","family":"Galigutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. N.","family":"Hasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7480-8761","authenticated-orcid":false,"given":"Krishna","family":"Undela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"3925_CR1","unstructured":"IDF Diabetes Atlas. 10th ed. Available from: https:\/\/diabetesatlas.org\/ (2023)"},{"key":"3925_CR2","doi-asserted-by":"publisher","first-page":"l5003","DOI":"10.1136\/bmj.l5003","volume":"366","author":"DJ Magliano","year":"2019","unstructured":"D.J. Magliano, R.M. Islam, E.L.M. Barr, E.W. Gregg, M.E. Pavkov, J.L. Harding et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ 366, l5003 (2019)","journal-title":"BMJ"},{"issue":"3","key":"3925_CR3","first-page":"235","volume":"9","author":"OR Temneanu","year":"2016","unstructured":"O.R. Temneanu, L.M. Trandafir, M.R. Purcarea, Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice. J. Med Life 9(3), 235\u2013239 (2016)","journal-title":"J. Med Life"},{"key":"3925_CR4","unstructured":"Y.A. Dom\u00ednguez, M. Emiliano, L. Puigi, J.H. Rodr\u00edguezi, Contribuci\u00f3n de la Epidemiolog\u00eda al estudio de la diabetes mellitus. Rev. Cubana Hig. Epidemiol. 55(2), 46\u201350 (2017)"},{"issue":"4","key":"3925_CR5","first-page":"91","volume":"19","author":"AEI Coria","year":"2017","unstructured":"A.E.I. Coria, A.A. Cort\u00e9s, O.F.R. de la Roche, E.C. Hern\u00e1ndez, La Diabetes Mellitus y sus implicaciones sociales y cl\u00ednicas en M\u00e9xico y Latinoam\u00e9rica Diabetes Mellitus and its Social and Clinical Implications in Mexico and Latin America. Archivos en. Med. Fam. 19(4), 91\u201394 (2017)","journal-title":"Archivos en. Med. Fam."},{"issue":"4","key":"3925_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41440-017-0001-5","volume":"41","author":"S Katayama","year":"2018","unstructured":"S. Katayama, M. Hatano, M. Issiki, Clinical features and therapeutic perspectives on hypertension in diabetics. Hypertension Res. 41(4), 213 (2018)","journal-title":"Hypertension Res."},{"issue":"4","key":"3925_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890.2011.560181","volume":"44","author":"G Musso","year":"2012","unstructured":"G. Musso, R. Gambino, M. Cassader, G. Pagano, A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann. Med. 44(4), 375\u2013393 (2012)","journal-title":"Ann. Med."},{"issue":"1","key":"3925_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1476-5381.2011.01340.x","volume":"164","author":"K Yamamoto","year":"2011","unstructured":"K. Yamamoto, S. Uchida, K. Kitano, N. Fukuhara, L. Okumura-Kitajima, E. Gunji et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br. J. Pharm. 164(1), 181\u2013191 (2011)","journal-title":"Br. J. Pharm."},{"issue":"10166","key":"3925_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"T.A. Zelniker, S.D. Wiviott, I. Raz, K. Im, E.L. Goodrich, M.P. Bonaca et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31\u201339 (2019)","journal-title":"Lancet"},{"issue":"1","key":"3925_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","volume":"20","author":"T Yamada","year":"2021","unstructured":"T. Yamada, M. Wakabayashi, A. Bhalla, N. Chopra, H. Miyashita, T. Mikami et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc. Diabetol. 20(1), 14 (2021)","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"3925_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/1574886313666180226103408","volume":"13","author":"M Singh","year":"2018","unstructured":"M. Singh, A. Kumar, Risks Associated with SGLT2 Inhibitors: An Overview. Curr. Drug Saf. 13(2), 84\u201391 (2018)","journal-title":"Curr. Drug Saf."},{"issue":"Suppl 1","key":"3925_CR12","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.amjcard.2019.10.029","volume":"124","author":"JB McGill","year":"2019","unstructured":"J.B. McGill, S. Subramanian, Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. Am. J. Cardiol. 124(Suppl 1), S45\u2013S52 (2019)","journal-title":"Am. J. Cardiol."},{"key":"3925_CR13","doi-asserted-by":"crossref","unstructured":"A. Tentolouris, P. Vlachakis, E. Tzeravini, I. Eleftheriadou, N. Tentolouris. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int. J. Environ. Res. Public Health. 16, 2965 (2019)","DOI":"10.3390\/ijerph16162965"},{"key":"3925_CR14","doi-asserted-by":"crossref","unstructured":"R. Pelletier, K. Ng, W. Alkabbani, Y. Labib, N. Mourad, J.M. Gamble, Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther. Adv. Drug Saf. 12, 2042098621989134 (2021)","DOI":"10.1177\/2042098621989134"},{"issue":"9","key":"3925_CR15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","volume":"154","author":"WL Bennett","year":"2011","unstructured":"W.L. Bennett, N.M. Maruthur, S. Singh, J.B. Segal, L.M. Wilson, R. Chatterjee et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann. Intern Med 154(9), 602\u2013618 (2011)","journal-title":"Ann. Intern Med"},{"issue":"5","key":"3925_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/2042018814553965","volume":"5","author":"B Peene","year":"2014","unstructured":"B. Peene, K. Benhalima, Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes. Ther. Adv. Endocrinol. Metab. 5(5), 124\u2013136 (2014)","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"7","key":"3925_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1185\/03007995.2014.912983","volume":"30","author":"Y Seino","year":"2014","unstructured":"Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, S. Sakai, Y. Samukawa, Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, phase 3 study. Curr. Med Res Opin. 30(7), 1245\u20131255 (2014)","journal-title":"Curr. Med Res Opin."},{"key":"3925_CR18","doi-asserted-by":"crossref","unstructured":"H. Kakinuma, T. Oi, Y. Hashimoto-Tsuchiya, M. Arai, Y. Kawakita, Y. Fukasawa et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J. Med. Chem. 53(8), 3247\u20133261 (2010)","DOI":"10.1021\/jm901893x"},{"issue":"7","key":"3925_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1507\/endocrj.EJ15-0097","volume":"62","author":"Y Seino","year":"2015","unstructured":"Y. Seino, K. Kaku, N. Inagaki, M. Haneda, T. Sasaki, A. Fukatsu et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Endocr. J. 62(7), 593\u2013603 (2015)","journal-title":"Endocr. J."},{"key":"3925_CR20","doi-asserted-by":"crossref","unstructured":"R. Hashimoto-Kameda, K.Y. Cho, H. Nomoto, A. Nakamura, K. Omori, S. Nagai, et al. Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). Diabetes Res Clin Pract. 180, 109069 (2021)","DOI":"10.1016\/j.diabres.2021.109069"},{"issue":"1","key":"3925_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clinthera.2015.10.025","volume":"38","author":"M Haneda","year":"2016","unstructured":"M. Haneda, Y. Seino, N. Inagaki, K. Kaku, T. Sasaki, A. Fukatsu et al. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin. Ther. 38(1), 66\u201388.e20 (2016)","journal-title":"Clin. Ther."},{"key":"3925_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021)","journal-title":"BMJ"},{"issue":"1","key":"3925_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17(1), 1\u201312 (1996)","journal-title":"Control Clin. Trials"},{"key":"3925_CR24","doi-asserted-by":"crossref","unstructured":"J.A.C. Sterne, J. Savovi\u0107, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 366, l4898 (2019)","DOI":"10.1136\/bmj.l4898"},{"issue":"2","key":"3925_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/dom.13061","volume":"20","author":"T Shibuya","year":"2018","unstructured":"T. Shibuya, N. Fushimi, M. Kawai, Y. Yoshida, H. Hachiya, S. Ito et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diab. Obes. Metab. 20(2), 438\u2013442 (2018)","journal-title":"Diab. Obes. Metab."},{"key":"3925_CR26","unstructured":"M. Sugawara, M. Fukuda, I. Sakuma, Y. Wakasa, H. Funayama, A. Kondo, et al. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study). Diabetes Ther. 14(9), (2023)"},{"issue":"3","key":"3925_CR27","doi-asserted-by":"publisher","first-page":"e003290","DOI":"10.1136\/bmjdrc-2022-003290","volume":"11","author":"M Shestakova","year":"2023","unstructured":"M. Shestakova, B. Kvasnikov, E. Erina, E. Isachenko, A. Andreev, Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial. BMJ Open Diab. Res Care 11(3), e003290 (2023)","journal-title":"BMJ Open Diab. Res Care"},{"key":"3925_CR28","doi-asserted-by":"crossref","unstructured":"K. Ejiri, T. Miyoshi, H. Kihara, Y. Hata, T. Nagano, A. Takaishi, et al. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. J Am Heart Assoc. 9(16), e015103 (2020)","DOI":"10.1161\/JAHA.119.015103"},{"issue":"7","key":"3925_CR29","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1185\/03007995.2014.901943","volume":"30","author":"Y Seino","year":"2014","unstructured":"Y. Seino, T. Sasaki, A. Fukatsu, S. Sakai, Y. Samukawa, Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30(7), 1219\u20131230 (2014)","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"3925_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/03007995.2018.1441816","volume":"34","author":"Y Seino","year":"2018","unstructured":"Y. Seino, T. Sasaki, A. Fukatsu, H. Imazeki, H. Ochiai, S. Sakai, Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Curr. Med. Res. Opin. 34(6), 981\u2013994 (2018)","journal-title":"Curr. Med. Res. Opin."},{"key":"3925_CR31","doi-asserted-by":"crossref","unstructured":"D. Dutta, J. Kadian, K. Mahajan, A. Dhall, M. Sharma, Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis. Diabetes Metab Syndr. 17(3), 102742 (2023)","DOI":"10.1016\/j.dsx.2023.102742"},{"issue":"8","key":"3925_CR32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s40265-014-0230-8","volume":"74","author":"A Markham","year":"2014","unstructured":"A. Markham, S. Elkinson, Luseogliflozin: first global approval. Drugs 74(8), 945\u2013950 (2014)","journal-title":"Drugs"},{"key":"3925_CR33","unstructured":"Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors - PubMed. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35015430\/ (2023)"},{"issue":"6 Suppl 1","key":"3925_CR34","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","volume":"40","author":"S Halimi","year":"2014","unstructured":"S. Halimi, B. Verg\u00e8s, Adverse effects and safety of SGLT-2 inhibitors. Diab. Metab. 40(6 Suppl 1), S28\u2013S34 (2014)","journal-title":"Diab. Metab."},{"issue":"48","key":"3925_CR35","doi-asserted-by":"publisher","first-page":"e5473","DOI":"10.1097\/MD.0000000000005473","volume":"95","author":"W Xiong","year":"2016","unstructured":"W. Xiong, M.Y. Xiao, M. Zhang, F. Chang, Efficacy and safety of canagliflozin in patients with type 2 diabetes. Medicine 95(48), e5473 (2016)","journal-title":"Medicine"},{"issue":"3","key":"3925_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/00325481.2017.1259544","volume":"129","author":"R Devi","year":"2017","unstructured":"R. Devi, G. Mali, I. Chakraborty, M.K. Unnikrishnan, S. Abdulsalim, Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Postgrad. Med. 129(3), 382\u2013392 (2017)","journal-title":"Postgrad. Med."},{"issue":"30","key":"3925_CR37","doi-asserted-by":"publisher","first-page":"e16575","DOI":"10.1097\/MD.0000000000016575","volume":"98","author":"M Feng","year":"2019","unstructured":"M. Feng, H. Lv, X. Xu, J. Wang, W. Lyu, S. Fu, Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus. Medicine 98(30), e16575 (2019)","journal-title":"Medicine"},{"issue":"7","key":"3925_CR38","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1185\/03007995.2014.909390","volume":"30","author":"Y Seino","year":"2014","unstructured":"Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, S. Sakai, Y. Samukawa, Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr. Med. Res. Opin. 30(7), 1231\u20131244 (2014)","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03925-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03925-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03925-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T11:30:55Z","timestamp":1729251055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03925-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["3925"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03925-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"4 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}